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Abstract 
Introduction:  Percutaneous nephrolithotomy (PCNL) is considered the gold standard for 
treatment of large renal calculi.  Although several investigators have examined the feasibility and 
outcomes associated with PCNL in obese patients, these studies have been limited by small 
sample size, lack of a comparator group, or few patients at body mass index (BMI) extremes.  We 
thus compared outcomes of super-obese (BMI>50) patients undergoing PCNL versus both an 
“overweight” and “ideal” cohort. 
 
Methods:  We used a prospectively maintained database to identify ideal (BMI 18.5-25), 
overweight (BMI 25.1-49.9), and super-obese (BMI≥50) patients who underwent PCNL.  Our 
primary objective was to compare surgical outcomes between groups as measured by the percent 
of patients who required secondary PCNL.  We then compared complication rates, need for 
transfusion, and length of stay (LOS) using chi-square testing and ANOVA where appropriate. 
 
Results:  A total of 1,152 patients were identified of which 254 were classified as ideal, 840 as 
overweight, and 58 as super-obese.  The overweight cohort had a higher mean age and greater 
proportion of males, whereas staghorn stones were more common in the super-obese group.  
Comorbid conditions were more commonly observed in the super-obese cohort.  Otherwise, the 
groups were similar.  Surgical outcomes were comparable with 47.2%, 42.0%, and 38.0% of 
ideal, overweight, and super-obese patients requiring secondary PCNL (p=0.25) with no 
difference in complication rates, need for transfusion, or LOS. 
 
Conclusion:  PCNL can be effectively and safely performed in super-obese patients with no 
difference in surgical outcomes or complications when compared to ideal or overweight patient 
cohorts. 
	 	
3	
	
Introduction 
Although there are several surgical modalities available for the treatment of renal calculi, 
percutaneous nephrolithotomy (PCNL) remains the reference standard for treatment of large 
stones, particularly those greater than 2cm in size.1,2  Indeed, a multitude of studies have been 
conducted which clearly indicate the effectiveness of PCNL while maintaining an acceptable 
safety profile.3-5  Importantly, these outcomes remain favorable despite stone configuration, size, 
location, or composition which stands in stark contrast to other surgical modalities, namely shock 
wave lithotripsy.6,7  
 Over the past few decades, obesity, defined as a body mass index (BMI, kg/m2) greater 
than 30, has become increasingly prevalent, reaching epidemic proportions.8  Given the 
association between obesity, metabolic syndrome, and kidney stones,9,10 these patients commonly 
present with large renal stones for which PCNL is the optimal surgical treatment.11  Several 
studies have documented the feasibility, safety, and efficacy of PCNL in obese patients.12-14  
However, limitations such as small sample size,15 lack of comparator groups,16,17 or few patients 
at BMI extremes18 have led some experts to assert that alternative treatment modalities, namely 
flexible ureteroscopy, be considered first-line therapy.19 
 Herein, we present our experience and outcomes following PCNL in patients across a 
wide range of BMI from a large, single-institutional, contemporary dataset.  Particular attention is 
focused on super-obese patients - those with a BMI greater than or equal to 50 - in whom PCNL 
can be exceptionally challenging.  Findings from this study are intended to bolster the existing 
evidence that PCNL is an acceptable and efficacious treatment for large renal stones irrespective 
of BMI and should be considered the standard treatment approach for these patients. 
 
Methods 
Data Source and Study Population 
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 Using a prospectively maintained, institutional review board-approved database 
(Methodist Hospital IRB#1010002243), we identified all adult patients who had undergone 
unilateral or bilateral PCNL at a single tertiary referral center.  This dataset includes over 1,250 
consecutive patients enrolled from the year 2003 to 2015 and treated by thirteen surgeons. 
 Since our primary focus was to determine how BMI might impact surgical outcomes, we 
further stratified patients into three groups.  Patients were categorized as ideal if their BMI was 
18.5-24.9, overweight if BMI was 25-49.9, or super-obese if BMI was greater than or equal to 50.  
Patients with a BMI less than 18.5 were excluded.  A wide range of BMI was intentionally 
included in the overweight cohort since prior studies have not documented any difference in 
outcomes for PCNL in patients with BMI ranging from 25 to in excess of 40 and this allowed for 
a larger sample size for comparison to the ideal and super-obese cohorts.13   
 
Surgical Considerations and Hospital Course 
Our surgical technique has been described in detail in other reports.20,21  In brief, after 
induction of general anesthesia, patients are positioned in the lithotomy position such that a 5F 
ureteral catheter can be advanced in retrograde fashion into the renal unit of interest to facilitate 
delineation of calyceal anatomy.  The patient is then positioned prone and secured to the 
operating room table.  A retrograde study is performed and the calyx of puncture, typically 
posteriorly oriented and lower pole, is selected.  Access is obtained using an 18-gauge diamond 
tip needle, biplanar fluoroscopy, and triangulation technique while respiration is suspended.   
After confirmation of entry into the collecting system by aspiration of urine, a 
hydrophilic wire is negotiated down the ureter with the aid of an angiographic catheter, if 
necessary.  The wire is exchanged for an Amplatz super stiff wire (Boston Scientific Corp, 
Natick, MA) and an 8-10F coaxial dilator is used to place a second safety wire.  A tract is then 
dilated using a 30F balloon and a 17 or 20cm Amplatz sheath is positioned into the calyx 
depending on the skin to calyx distance. Stone material is removed using an Olympus LUS-2 
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ultrasonic lithotripter (Olympus, Center Valley, PA) after which time the kidney is carefully 
inspected with a flexible nephroscope in order to visualize each and every calyx.  Upon 
completion, a 10F Cope nephrostomy tube is positioned in the kidney and a 5F ureteral catheter is 
advanced down the ureter to facilitate access should secondary PCNL be required. 
The morning following surgery, a non-contrast computed tomography scan (CT) is 
performed to document tube position and stone burden.  Patients with residual stone burden are 
taken back to the operating room for secondary PCNL within 24 to 48 hours.  Once all stones 
have been cleared, an antegrade nephrostogram is performed to confirm renal drainage and the 
nephrostomy tube is removed before discharge.  
 
Outcome Measures and Statistical Analysis 
 We began by comparing patients in each BMI cohort across a range of demographic 
factors.  We correlated the degree of comorbidity between groups by defining the proportion of 
patients with diagnoses for hypertension, renal insufficiency, diabetes, and gout.  We further 
compared stone size measured as maximal stone dimension on CT, stone configuration (staghorn 
vs. non-staghorn), and stone analysis between groups.  Stone analysis was performed by a single 
laboratory (Beck Laboratories, Greenwood, Indiana) with stones categorized based on 
predominant mineral subtype (e.g. calcium oxalate, calcium phosphate, etc.).  The number of 
accesses performed at the time of primary PCNL and case duration (defined as time from surgical 
incision to final nephrostomy tube placement) were also recorded and compared as a measure of 
case complexity. 
 
 Our primary objective was to compare the outcomes of PCNL amongst the three patient 
cohorts.  We assessed procedure efficacy by determining the proportion of patients in whom 
secondary PCNL was performed.  As described earlier, secondary PCNL is performed in patients 
with any residual stone burden on post-operative CT and, thus, approximates stone free rate.  We 
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then compared mean overall complication rate stratified by Clavien index, rate of blood 
transfusion, and length of stay (LOS). 
 Statistical analysis was conducted with IBM® SPSS® Statistics, Version 22.  We 
performed chi-square testing for categorical variables and ANOVA for continuous variables 
using two-sided significance testing with alpha set at 0.05 for all comparisons.  
 
Results 
We identified a total of 1,152 patients of which 254 (22.0%) were classified as ideal, 840 
(73.0%) as overweight, and 58 (5.0%) as super-obese based on BMI.  The mean BMI in the ideal, 
overweight, and super-obese cohorts was 22.3 (range 18.5 to 25), 32.9 (range 25.1 to 49.9), and 
56.6, (range 50 to 75.9) respectively.  Whereas older patients were more heavily represented in 
the overweight cohort, a significantly greater proportion of females were found in the super-obese 
cohort.  Comorbid conditions were present in increasing proportions as BMI increased such that 
those in the super-obese cohort had significantly higher rates of hypertension, diabetes, and gout 
relative to the overweight and ideal cohort, respectively.  While a staghorn stone configuration 
was more common in the super-obese cohort, stone size and case complexity, indicated by 
proportion of cases requiring more than one access and case duration, did not differ between 
groups (Table 1).  Stone analysis data is presented in Table 2.  Calcium phosphate stones were 
more common in patients in the ideal cohort whereas a greater proportion of uric acid stones were 
observed in the overweight and super-obese cohorts. 
 Surgical efficacy was similar between groups with 47.2%, 42.0%, and 38.0% of ideal, 
overweight, and super-obese patients requiring secondary PCNL (p=0.25).  The overall mean 
complication rate was not statistically different between groups (12.6% ideal vs. 12.8% 
overweight vs. 15.5% super-obese; p=0.66).  Table 3 indicates the breakdown of complications 
stratified by Clavien grade.  The majority of complications observed were relatively minor 
(Clavien grade 1 or 2) and no difference in complication severity was observed between BMI 
7	
	
groups (Figure 1).  There was no difference observed between ideal, overweight, or super-obese 
patients relative to mean rate of blood transfusion (4.3% vs. 3.1% vs. 3.4%; p=0.63) or LOS (2.5 
days vs. 2.4 days vs. 3.0 days; p=0.12). 
 
Discussion 
 In the largest single-institution study to date, we investigated the outcomes of PCNL in 
more than 1,150 subjects across a range of BMI extremes.  In particular, we compared surgical 
outcomes in the super-obese against those with lesser BMI, an area which has not been previously 
reported.  Super-obese patients more often had staghorn calculi, possibly reflecting the referral 
nature of our practice and lack of experience in community settings with these challenging 
patients.  The super-obese patients also suffered from higher degrees of comorbidity than their 
overweight or ideal weight counterparts and had a higher proportion of uric acid stones, a finding 
consistent with reports from other investigators.22  Despite these facts, surgical outcomes did not 
differ.  Furthermore, overall complication rates and severity were comparable between BMI 
groups indicating that PCNL can be safely performed even at BMI extremes. 
 Our results are consistent with other published studies which report no difference in 
stone-free rates or operative complications as BMI increases.12,13,18  Interestingly, in the largest 
study to date on the topic, Fuller et al, in a large, multi-center study from the Clinical Research 
Office of the Endourological Society (CROES), found that stone-free rates were inversely related 
to increasing BMI albeit with no difference in complication rates.  This disparity is possibly 
related to the single- versus multi-institutional nature of the two studies.  Whereas we report 
outcomes from a single, tertiary referral center with expertise in urinary stone disease, the 
CROES study synthesizes data from 96 centers, some of which may perform few PCNL on obese 
patients, thus skewing outcomes to give the impression of an inverse association. 
 The finding that PCNL outcomes are satisfactory in even super-obese patients speaks to 
the favorable intersection between equipment advances with the training and expertise of modern 
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endourologists.  Recently, Streeper and colleagues reported their outcomes in 31 patients with a 
BMI greater than 50 (mean 59.1).  They noted that access to specialized equipment such as extra-
long access needles, Amplatz sheaths, and nephroscopes was of paramount importance and, 
admirably, they reported no failures to obtain access.16  In a similar study also including patients 
with a BMI in excess of 50, Keheila et al reported their outcomes of 21 PCNL in patients with a 
mean BMI of 57.2.  Stone-free rates approximated 87% and complication rates were comparable 
to contemporary series.  They emphasize the importance of the entire care team, incorporating an 
anesthesiologist comfortable with prone positioning and airway concerns in obese patients.17  
 While the two previously described studies have demonstrated the feasibility of PCNL in 
even the largest patients, ours is the first to indicate acceptable outcomes with PCNL in a direct 
comparison between super-obese patients and those with lower BMI.  These findings are 
important in the context of the increasing use of flexible ureteroscopy, especially for larger renal 
stones.23,24  In fact, investigators have suggested that ureteroscopy may indeed be the treatment of 
choice for obese patients with renal stones based on perceived difficulties associated with PCNL 
in this patient group.19  Doizi et al, retrospectively reviewed their experience with ureteroscopy in 
normal weight, obese, and morbidly obese patients and found that success rates overall were 
roughly 68% for a single procedure.  Complications were rare, reported at 2%, leading 
investigators to suggest that ureteroscopy may be the preferred treatment for renal stones in obese 
patients.   
This assertion must be tempered by several factors.  First, success rate was defined by 
absence of residual fragments >2mm, an outcome measure of debate amongst urologists.25  
Furthermore, many patients underwent a plain radiograph and ultrasound at follow-up, a 
limitation conceded by the investigators.  Second, only 14 procedures were included in the 
morbidly obese group, defined as BMI greater than 40, limiting generalizability of these 
outcomes, especially given the relatively low success rate after two procedures in this group of 
78.6%.  Finally, although complication rates were certainly lower than we report for PCNL, other 
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studies describing ureteroscopy in obese patients indicate complication rates comparable to our 
results.26  
  In our experience, though the super-obese patient provides unique challenges, we do not 
typically deviate from our normal procedure.  The patient is positioned prone because although 
peak inspiratory airway pressures are known to be increased in obese patients, this is independent 
of prone or supine positioning.27  Care is taken to judiciously pad all potential pressure points to 
prevent nerve or tissue injury and the patient is securely fastened to the table to prevent shifting.  
Like other investigators, we employ long instruments when necessary and perform judicious 
flexible nephroscopy, not unlike any other PCNL.  In the event that even with long instruments, 
the calyx of interest is unable to be reached, a larger skin incision can be made to prevent hubbing 
of the access needle or nephroscope against the skin and facilitate further advancement of the 
Amplatz sheath.  Exit strategies are of particular importance in the super-obese patient as 
nephrostomy tube dislodgement is common.28  Since secondary PCNL is performed in more than 
one third of these patients, durable access to the collecting system is vital.  Efforts to position the 
10F Cope loop in a polar calyx opposite that which was punctured rather than the renal pelvis 
may limit tube expulsion and routine placement of a 5F catheter down the ipsilateral ureter is 
essential. 
 Our study must be viewed within the context of some limitations.  First, although the 
database is prospectively maintained, we report retrospective results.  Thus, our results may be 
vulnerable to bias inherent in retrospective studies.  This limitation should be mitigated, to a 
degree, by the large sample size presented in the current study.  Second, we report outcomes 
measured by the proportion of patients who went on to require a secondary PCNL rather than 
stone free rate.  While stone free rate is the most widely accepted outcome measure for renal 
stone surgery, its definition is not without controversy, namely what is truly considered stone 
free.  We judiciously map the collecting system with a flexible nephroscope at the time of 
secondary PCNL and perform basket extraction of all stone fragments.  It is assumed that results 
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of secondary PCNL correlate with stone free rate.  While the number of surgeons (13) performing 
PCNL in this study is large, and could introduce procedural variability impacting results, the vast 
majority of cases (>95%) were performed by a single surgeon (JEL). Finally, we report our 
experience from a tertiary referral center and perform several hundred PCNL annually.  As such, 
our outcomes may not be generalizable to all practicing urologists in whom exposure to super-
obese patients needing percutaneous surgery may be significantly less frequent. 
 
Conclusion 
 PCNL can be safely and effectively performed in super-obese patients, with no 
significant differences in complications or outcomes when compared to overweight or ideal body 
weight individuals.  Appropriate surgical planning with particular attention to proper 
instrumentation is important to ensure a desirable outcome.  In the absence of a prospective, 
direct comparison between PCNL and ureteroscopy for large renal stones in super-obese patients, 
it is likely that urologists will choose whichever procedure they feel best trained to perform, 
though referral to a center with expertise in PCNL should be strongly considered in these patients. 
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Table	1	–	Comparison	of	mean	demographics,	comorbidity,	and	case	complexity	
between	groups.	
		
Ideal	
BMI	18.5‐25	
(n=254)	
Overweight	
BMI	25.1‐49.9	
(n=840)	
Super‐Obese	
BMI>50	
(N=58)	
P‐value
Age	(years)	 50.9	 54.7	 52.4	 <0.01	
Male	(%)	 42.1	 53.5	 25.9	 <0.01	
Hypertension	(%)	 24.4	 51.5	 60.6	 <0.01	
Renal	Insufficiency	(%)	 2.4	 1.8	 3.0	 0.69	
Diabetes	(%)	 6.2	 24.4	 43.9	 <0.01	
Gout	(%)	 0.7	 4.6	 6.1	 <0.01	
Stone	size	(range,	cm)	 2.6	(0.3‐10.7)	 2.6	(0.3‐9.4)	 2.8	(0.3‐6.0)	 0.21	
Staghorn	(%)	 28	 33.5	 43.9	 0.04	
>1	access	(%)	 35	 32.3	 34.5	 0.69	
Case	duration	(minutes)	 125.3	 128	 126.7	 0.78	
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Table 2:  Stone analysis comparison by BMI group 
  
Ideal 
BMI 18.5-25 
(%) 
Overweight 
BMI 25.1-49.9 
(%) 
Super-Obese 
BMI>50 
(%) 
P-value 
Calcium oxalate 43.4 45.4 43.8 0.98 
Calcium phosphate 39.7 31.6 34.4 0.04 
Uric acid 3.1 11.4 12.5 <0.01 
Struvite 5.2 4.0 3.1 0.59 
Cystine 2.4 2.8 0 0.39 
Other 1.4 1.2 1.6 0.94 
Unknown 4.8 3.6 4.6 0.86 
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Table 3:  Number of complications in each group stratified by Clavien system 
 Ideal 
BMI 18.5-25 
(n=32) 
Overweight 
BMI 25.1-49.9 
(n=108) 
Super Obese 
BMI>50 
(n=9) 
Clavien I (%) 12 (37.5) 44 (40.7) 4 (44.4) 
Clavien II (%) 9 (28.1) 31 (28.7) 2 (22.2) 
Clavien IIIa (%) 6 (18.8) 18 (16.7) 1 (11.1) 
Clavien IIIb (%) 4 (12.5) 9 (8.3) 1 (11.1) 
Clavien Iva (%) 1 (3.1) 3 (2.8) 0 (0) 
Clavien IVb (%) 0 (0) 2 (1.9) 1 (11.1) 
Clavien V (%) 0 (0) 1 (0.9) 0 (0) 
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Figure 1:  Among patients with complications, proportion with Clavien Grade <3 
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